Patents by Inventor Barbara Haeberlin

Barbara Haeberlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions
    Publication number: 20030008835
    Abstract: A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.
    Type: Application
    Filed: July 12, 2002
    Publication date: January 9, 2003
    Inventors: Patrice Guitard, Barbara Haeberlin, Rainer Link, Friedrich Richter
  • Oil-free pharmaceutical compositions containing cyclosporin A
    Patent number: 6475519
    Abstract: The present invention provides a hard gelatine capsule containing a pharmaceutical composition comprising cyclosporin A in a mixture with a surfactant of HLB value of at least 10, substantially free of any oil and when a hydrophilic phase is present, the hydrophilic phase being a polyethylene glycol and/or a lower alkanol provided that any lower alkanol, if present, is present in less than 12% of the total weight of the composition absent the hard gelatine capsule.
    Type: Grant
    Filed: April 13, 1999
    Date of Patent: November 5, 2002
    Assignee: Novartis AG
    Inventors: Armin Meinzer, Barbara Haeberlin
  • Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
    Patent number: 6455518
    Abstract: A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: September 24, 2002
    Assignee: Novartis AG
    Inventors: Gerhard Zenke, Hendrik Schuurman, Barbara Haeberlin, Armin Meinzer
  • Oil-free pharmaceutical compositions containing cyclosporin A
    Publication number: 20020119190
    Abstract: The present invention provides a hard gelatine capsule containing a pharmaceutical composition comprising cyclosporin A in a mixture with a surfactant of HLB value at least 10, substantially free of any oil and when a hydrophilic phase is present, the hydrophilic phase being a polyethylene glycol and/or a lower alkanol provided that any lower alkanol present is present in less than 12% of the total weight of the composition absent the hard gelatine capsule.
    Type: Application
    Filed: November 6, 2001
    Publication date: August 29, 2002
    Inventors: Armin Meinzer, Barbara Haeberlin
  • Spontaneously dispersible N-benzoyl staurosporine compositions
    Publication number: 20020061873
    Abstract: Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment.
    Type: Application
    Filed: August 15, 2001
    Publication date: May 23, 2002
    Inventors: Graham Paul Matthews, Barbara Haeberlin
  • Enteric coated pharmaceutical compositions
    Patent number: 6306900
    Abstract: This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.
    Type: Grant
    Filed: October 23, 2000
    Date of Patent: October 23, 2001
    Assignee: Novartis AG
    Inventors: Barbara Haeberlin, Ching-Pong Mak, Armin Meinzer, Jacky Vonderscher
  • Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-O-(2-hydroxyethyl)-rapamycin
    Publication number: 20010008888
    Abstract: A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
    Type: Application
    Filed: January 11, 2001
    Publication date: July 19, 2001
    Inventors: Gerhard Zenke, Hendrik Schuurman, Barbara Haeberlin, Armin Meinzer
  • Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
    Patent number: 6239124
    Abstract: A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
    Type: Grant
    Filed: January 28, 1999
    Date of Patent: May 29, 2001
    Assignee: Novartis AG
    Inventors: Gerhard Zenke, Hendrik Schuurman, Barbara Haeberlin, Armin Meinzer
  • Pharmaceutical compositions
    Patent number: 6197781
    Abstract: A pharmaceutical composition in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin or an ascomycin, and a carrier medium.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: March 6, 2001
    Assignee: Novartis AG
    Inventors: Patrice Guitard, Barbara Haeberlin, Rainer Link, Friedrich Richter
  • Entric-coated pharmaceutical compositions
    Patent number: 6172107
    Abstract: This invention provides a pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.
    Type: Grant
    Filed: December 22, 1999
    Date of Patent: January 9, 2001
    Assignee: Novartis AG
    Inventors: Barbara Haeberlin, Ching-Pong Mak, Armin Meinzer, Jacky Vonderscher
  • Enteric-coated pharmaceutical compositions of mycophenolate
    Patent number: 6025391
    Abstract: Disclosed are pharmaceutical compositions which have been modified to release pharmaceutically acceptable mycophenolate salts in the upper part of the intestinal tract and methods of treatment using the pharmaceutical compositions.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: February 15, 2000
    Assignee: Novartis AG
    Inventors: Barbara Haeberlin, Ching-Pong Mak, Armin Meinzer, Jacky Vonderscher
  • Pharmaceutical compositions comprising rafamycin coprecipitates
    Patent number: 6004973
    Abstract: Disclosed are pharmaceutical compositions containing solid dispersions in the form of co-precipitates, which solid dispersions contain rapamycin and a carrier medium, and methods of treatment utilizing such pharmaceutical compositions.
    Type: Grant
    Filed: January 26, 1998
    Date of Patent: December 21, 1999
    Assignee: Novartis AG
    Inventors: Patrice Guitard, Barbara Haeberlin, Rainer Link, Friedrich Richter
  • Galenical formulations
    Patent number: 5932243
    Abstract: A pharmaceutical composition containing macrolide, e.g. a rapamycin compound in an emulsion preconcentrate or microemulsion preconcentrate for oral administration. The carrier medium for the rapamycin compound includes a hydrophilic phase, a lipophilic phase and a surfactant. The composition is stable and provides high absorption efficiency.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: August 3, 1999
    Assignee: Novartis AG
    Inventors: Gerd Fricker, Barbara Haeberlin, Armin Meinzer, Jacky Vonderscher